363 related articles for article (PubMed ID: 23728943)
1. Identification of driver genes in hepatocellular carcinoma by exome sequencing.
Cleary SP; Jeck WR; Zhao X; Chen K; Selitsky SR; Savich GL; Tan TX; Wu MC; Getz G; Lawrence MS; Parker JS; Li J; Powers S; Kim H; Fischer S; Guindi M; Ghanekar A; Chiang DY
Hepatology; 2013 Nov; 58(5):1693-702. PubMed ID: 23728943
[TBL] [Abstract][Full Text] [Related]
2. The genomic landscape of hepatoblastoma and their progenies with HCC-like features.
Eichenmüller M; Trippel F; Kreuder M; Beck A; Schwarzmayr T; Häberle B; Cairo S; Leuschner I; von Schweinitz D; Strom TM; Kappler R
J Hepatol; 2014 Dec; 61(6):1312-20. PubMed ID: 25135868
[TBL] [Abstract][Full Text] [Related]
3. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
[TBL] [Abstract][Full Text] [Related]
4. Nuclear factor erythroid 2-related factor 2 and β-Catenin Coactivation in Hepatocellular Cancer: Biological and Therapeutic Implications.
Tao J; Krutsenko Y; Moghe A; Singh S; Poddar M; Bell A; Oertel M; Singhi AD; Geller D; Chen X; Lujambio A; Liu S; Monga SP
Hepatology; 2021 Aug; 74(2):741-759. PubMed ID: 33529367
[TBL] [Abstract][Full Text] [Related]
5. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
[TBL] [Abstract][Full Text] [Related]
6. Target genes discovery through copy number alteration analysis in human hepatocellular carcinoma.
Gu DL; Chen YH; Shih JH; Lin CH; Jou YS; Chen CF
World J Gastroenterol; 2013 Dec; 19(47):8873-9. PubMed ID: 24379610
[TBL] [Abstract][Full Text] [Related]
7. Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations.
Vilarinho S; Erson-Omay EZ; Harmanci AS; Morotti R; Carrion-Grant G; Baranoski J; Knisely AS; Ekong U; Emre S; Yasuno K; Bilguvar K; Günel M
J Hepatol; 2014 Nov; 61(5):1178-83. PubMed ID: 25016225
[TBL] [Abstract][Full Text] [Related]
8. TERT promoter mutations and chromosome 8p loss are characteristic of nonalcoholic fatty liver disease-related hepatocellular carcinoma.
Ki Kim S; Ueda Y; Hatano E; Kakiuchi N; Takeda H; Goto T; Shimizu T; Yoshida K; Ikura Y; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Uemoto S; Chiba T; Ogawa S; Marusawa H
Int J Cancer; 2016 Dec; 139(11):2512-8. PubMed ID: 27511114
[TBL] [Abstract][Full Text] [Related]
9. Liver expression of Nrf2-related genes in different liver diseases.
Cheng ML; Lu YF; Chen H; Shen ZY; Liu J
Hepatobiliary Pancreat Dis Int; 2015 Oct; 14(5):485-91. PubMed ID: 26459724
[TBL] [Abstract][Full Text] [Related]
10. NRF2 DLG Domain Mutations Identified in Japanese Liver Cancer Patients Affect the Transcriptional Activity in HCC Cell Lines.
Haque E; Śmiech M; Łuczyńska K; Bouchard MF; Viger R; Kono H; Pierzchała M; Taniguchi H
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069882
[TBL] [Abstract][Full Text] [Related]
11. Profiling of exome mutations associated with progression of HBV-related hepatocellular carcinoma.
Woo HG; Kim SS; Cho H; Kwon SM; Cho HJ; Ahn SJ; Park ES; Lee JS; Cho SW; Cheong JY
PLoS One; 2014; 9(12):e115152. PubMed ID: 25521761
[TBL] [Abstract][Full Text] [Related]
12. Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.
Zhang W; He H; Zang M; Wu Q; Zhao H; Lu LL; Ma P; Zheng H; Wang N; Zhang Y; He S; Chen X; Wu Z; Wang X; Cai J; Liu Z; Sun Z; Zeng YX; Qu C; Jiao Y
Gastroenterology; 2017 Jul; 153(1):249-262.e2. PubMed ID: 28363643
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the KEAP1-NFE2L2 Pathway Define a Molecular Subset of Rapidly Progressing Lung Adenocarcinoma.
Goeman F; De Nicola F; Scalera S; Sperati F; Gallo E; Ciuffreda L; Pallocca M; Pizzuti L; Krasniqi E; Barchiesi G; Vici P; Barba M; Buglioni S; Casini B; Visca P; Pescarmona E; Mazzotta M; De Maria R; Fanciulli M; Ciliberto G; Maugeri-Saccà M
J Thorac Oncol; 2019 Nov; 14(11):1924-1934. PubMed ID: 31323387
[TBL] [Abstract][Full Text] [Related]
14. Germline and somatic DICER1 mutations in familial and sporadic liver tumors.
Caruso S; Calderaro J; Letouzé E; Nault JC; Couchy G; Boulai A; Luciani A; Zafrani ES; Bioulac-Sage P; Seror O; Imbeaud S; Zucman-Rossi J
J Hepatol; 2017 Apr; 66(4):734-742. PubMed ID: 28012864
[TBL] [Abstract][Full Text] [Related]
15. Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.
Guichard C; Amaddeo G; Imbeaud S; Ladeiro Y; Pelletier L; Maad IB; Calderaro J; Bioulac-Sage P; Letexier M; Degos F; Clément B; Balabaud C; Chevet E; Laurent A; Couchy G; Letouzé E; Calvo F; Zucman-Rossi J
Nat Genet; 2012 May; 44(6):694-8. PubMed ID: 22561517
[TBL] [Abstract][Full Text] [Related]
16. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
17. Tumor hepatitis B virus RNA identifies a clinically and molecularly distinct subset of hepatocellular carcinoma.
Lim HC; Gordan JD
PLoS Comput Biol; 2021 Feb; 17(2):e1008699. PubMed ID: 33561166
[TBL] [Abstract][Full Text] [Related]
18. Distinct pattern of TP53 mutations in human immunodeficiency virus-related head and neck squamous cell carcinoma.
Gleber-Netto FO; Zhao M; Trivedi S; Wang J; Jasser S; McDowell C; Kadara H; Zhang J; Wang J; William WN; Lee JJ; Nguyen ML; Pai SI; Walline HM; Shin DM; Ferris RL; Carey TE; Myers JN; Pickering CR;
Cancer; 2018 Jan; 124(1):84-94. PubMed ID: 29053175
[TBL] [Abstract][Full Text] [Related]
19. MiR-141 Activates Nrf2-Dependent Antioxidant Pathway via Down-Regulating the Expression of Keap1 Conferring the Resistance of Hepatocellular Carcinoma Cells to 5-Fluorouracil.
Shi L; Wu L; Chen Z; Yang J; Chen X; Yu F; Zheng F; Lin X
Cell Physiol Biochem; 2015; 35(6):2333-48. PubMed ID: 25896253
[TBL] [Abstract][Full Text] [Related]
20. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
Schulze K; Imbeaud S; Letouzé E; Alexandrov LB; Calderaro J; Rebouissou S; Couchy G; Meiller C; Shinde J; Soysouvanh F; Calatayud AL; Pinyol R; Pelletier L; Balabaud C; Laurent A; Blanc JF; Mazzaferro V; Calvo F; Villanueva A; Nault JC; Bioulac-Sage P; Stratton MR; Llovet JM; Zucman-Rossi J
Nat Genet; 2015 May; 47(5):505-511. PubMed ID: 25822088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
